Saturday, 31 October 2026European Markets

KLEPIERRE And FREY Have A High Dividend Yield And Return On Equity In The REIT—Retail Industry.

Loading stream...

(vianews) - klepierre (li.pa) is among this list of stock assets with the highest dividend rate and return on equity on the reit—retail industry.

financial asset price forward dividend yield return on equity
klepierre (li.pa) €24.75 7.8% 1.26%
frey (frey.pa) €25.60 5.9% 9.92%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. klepierre (li.pa)

7.8% forward dividend yield and 1.26% return on equity

klépierre is the european leader in shopping malls, combining property development and asset management skills. the company's portfolio is valued at €19.4 billion at june 30, 2023, and comprises large shopping centers in more than 10 countries in continental europe which together host hundreds of millions of visitors per year. klépierre holds a controlling stake in steen & strøm (56.1%), scandinavia's number one shopping center owner and manager. klépierre is a french reit (siic) listed on euronext paris and is included in the cac next 20 and epra euro zone indexes. it is also included in ethical indexes, such as euronext cac 40 esg, cac sbt 1.5, msci europe esg leaders, ftse4good, euronext vigeo europe 120, and features in cdp's "a-list". these distinctions underscore the group's commitment to a proactive sustainable development policy and its global leadership in the fight against climate change.

earnings per share

as for profitability, klepierre has a trailing twelve months eps of €0.6.

pe ratio

klepierre has a trailing twelve months price to earnings ratio of 41.25. meaning, the purchaser of the share is investing €41.25 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1.26%.

more news about klepierre.

2. frey (frey.pa)

5.9% forward dividend yield and 9.92% return on equity

frey sa engages in developing, owning, and managing commercial real estate assets primarily located in france. the company primarily operates environmental retail parks. as of december 31, 2010, its assets included 62,000 square meters. the company was formerly known as immobiliere frey sa and changed its name to frey sa in june 2009. frey sa was founded in 1983 and is based in reims, france.

earnings per share

as for profitability, frey has a trailing twelve months eps of €3.27.

pe ratio

frey has a trailing twelve months price to earnings ratio of 7.83. meaning, the purchaser of the share is investing €7.83 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.92%.

revenue growth

year-on-year quarterly revenue growth grew by 18.2%, now sitting on 134.96m for the twelve trailing months.

moving average

frey's value is way under its 50-day moving average of €30.97 and way below its 200-day moving average of €32.93.

more news about frey.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com